YOUR FAVORITES. YOUR VOTE. 2026 CAPPIES: Vote HERE

Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

698.79 -14.08 (-1.97%)
Streaming Delayed Price Updated: 1:18 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
News headline image
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times ↗
The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions. 
Via Benzinga
News headline image
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
Positive opinion based on results of Phase 3 C-POST trial that show Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence... 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Gapping S&P500 stocks in Monday's session ↗
Via Chartmill
Why Regeneron Pharmaceuticals’ Stock Is Climbing Premarket Today ↗
Via Stocktwits
News headline image
Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program ↗
The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks. 
Via Stocktwits
News headline image
Regeneron Pharmaceuticals (NASDAQ:REGN) Presents a Compelling Case for Value Investors ↗
Regeneron (REGN) presents a strong value investment case with a low P/E ratio, robust financial health, high profitability, and steady growth. 
Via Chartmill
News headline image
EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study ↗
EyePoint Pharmaceuticals outlines Phase 3 trials for Duravyu in diabetic macular edema, backed by $150 million in new funding. 
Via Benzinga
News headline image
Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers
New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinoma 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Stocks Down 17% and 21% to Buy Right Now ↗
Both companies have faced recent challenges, but look likely to overcome them. 
Via The Motley Fool
Topics World Trade
News headline image
Why Are Regeneron And Scholar Rock Shares Falling On Monday? ↗
Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk. 
Via Stocktwits
News headline image
Regeneron's Gene Therapy Shows Significant Gains In Genetic Hearing Loss ↗
Regeneron gene therapy for OTOF-related hearing loss shows rapid, sustained improvements, including normal hearing in some participants. 
Via Benzinga
News headline image
DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Forecasting The Future: 9 Analyst Projections For Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
Regeneron's Libtayo Gains FDA Approval To Reduce Recurrence Risk In Skin Cancer Patients ↗
FDA approves Regeneron's Libtayo for adults with high-risk cutaneous squamous cell carcinoma after surgery and radiation, based on Phase 3 trial data. 
Via Benzinga
News headline image
Investors Brace for Pullback as Short-Bias ETF Inflows Signal Growing Bearishness
A significant surge in capital flowing into short-bias Exchange-Traded Funds (ETFs) has sent a clear signal through the financial markets: investor sentiment is shifting towards caution and a potential... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out ↗
The small biotech company is looking to take on Regeneron and Sanofi's blockbuster, Dupixent. 
Via Investor's Business Daily
News headline image
Retail Buzz Builds Around Regeneron After FDA Clears Libtayo For High-Risk Skin Cancer; Traders Eye ‘Buying Opportunity’ ↗
The FDA’s approval of Libtayo was based on Phase 3 trial data showing a 68% reduction in the risk of recurrence or death in high-risk CSCC patients. 
Via Stocktwits
News headline image
Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September ↗
Results of the Resolve-AD trial with rezpegaldesleukin were better than expected. 
Via The Motley Fool
News headline image
A Look Into Regeneron Pharmaceuticals Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
Wednesday's session: top gainers and losers in the S&P500 index ↗
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday. 
Via Chartmill
News headline image
Health Care Stocks Rally, Nike Beats The Street: What's Moving Markets Wednesday? ↗
Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps markets afloat. 
Via Benzinga
News headline image
Which S&P500 stocks are moving on Wednesday? ↗
Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
News headline image
Nvidia, Amphenol, Lockheed Martin And A Health Care Stock On CNBC's 'Final Trades' ↗
Nvidia surges past 52-week high, surpasses $4.5 trillion market cap as tech companies invest in AI. Regeneron and Amphenol named as top trades. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Acuity, Lithium Americas, Rezolve AI, AES And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
Topics Artificial Intelligence
News headline image
Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Beaten-Down Stocks to Buy and Hold for a Decade ↗
These biotechs should benefit from their innovative ways. 
Via The Motley Fool
News headline image
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by... 
Via MarketMinute
News headline image
1 Healthcare Stock with Exciting Potential and 2 We Ignore
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This... 
Via StockStory
Topics Stocks
News headline image
FDA Expands Use Of Regeneron's Evkeeza To Infants With Rare Cholesterol Disorder ↗
The U.S. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Gift this article